T
Tiburio Therapeutics
Advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases
About Tiburio Therapeutics
Tiburio Therapeutics, Inc. is dedicated to developing transformative treatments for rare endocrine diseases, focusing on non-functioning pituitary adenomas (NFPAs) and other rare endocrine disorders. The company operates in the biopharmaceutical sector, targeting a niche market of patients with limited treatment options. Tiburio's clinical-stage pipeline includes two novel dopamine somatostatin chimeric compounds: TBR 760 and TBR 065. TBR 760 is designed to inhibit NFPA cell proliferation, potentially shrinking or halting tumor growth, and is expected to enter Phase 2 clinical trials. TBR 065 targets additional rare endocrine diseases. The business model revolves around advancing these compounds through clinical trials, securing regulatory approvals, and eventually commercializing the treatments. Revenue generation will primarily come from the sale of these specialized therapies to healthcare providers and institutions.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2019 | $31M | $124M | Lundbeckfonden Ventures · Longitude Capital · Alexandria Venture Investments · NEA | ↗ |
Growth signals
Latest recorded traffic for Tiburio Therapeutics is 300 monthly website visits, up 36.4% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tiburio Therapeutics in the Cambridge ecosystem
The Tiburio Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Lundbeckfonden Ventures
Longitude Capital
Alexandria Venture Investments
NEA
Other known investors1 additional known investor
Lundbeckfonden
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tiburio Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tiburio Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








